474
Views
13
CrossRef citations to date
0
Altmetric
Pulmonology

Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study

, , , , &
Pages 1789-1795 | Received 30 Jul 2015, Accepted 05 Jul 2016, Published online: 09 Sep 2016

References

  • Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8
  • Saiman L, Siegel J, LiPuma J, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014;35:S1-S67
  • Bhatt JM. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev 2013;22:205-16
  • Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187:680-9
  • Geller DE, Konstan MW, Smith J, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42:307-13
  • Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10:54-61
  • Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in the normal maximal expiratory flow–volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-34
  • Council For Clinical Certification in Audiology and Speech-Language Pathology of the American Speech-Language-Hearing Association. Standards for the Certificate of Clinical Competence in Audiology, 2012. Available at: http://www.asha.org/Certification/2012-Audiology-Certification-Standards/[Last accessed 30 September 2014]
  • Konstan MW. Long-term safety and efficacy of tobramycin inhalation powder in cystic fibrosis patients with P. aeruginosa: the edit trial and its two open-label extension studies. 27th North American Cystic Fibrosis Conference 2013, Salt Lake City, UT, USA, 2013
  • Harrison MJ, McCarthy M, Fleming C, et al. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros 2014;13:692-8
  • Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011;46:230-8
  • Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45:1121-34
  • Thompson V, Kloster M, Flume PA, et al. Hemoptysis is associated with underlying disease severity and is an expected adverse event in cystic fibrosis clinical trials. Pediatr Pulmonol 2014;49:352-3
  • Galeva I, Konstan MW, Higgins M, et al. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr Med Res Opin 2013;29:947-56
  • Liou TG, Elkin EP, Pasta DJ, et al. Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros 2010;9:250-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.